Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P13639
UPID:
EF2_HUMAN
Alternative names:
-
Alternative UPACC:
P13639; A0A384N6H1; B2RMP5; D6W618; Q58J86
Background:
Elongation factor 2 (EF-2) plays a pivotal role in protein synthesis, catalyzing the GTP-dependent ribosomal translocation step during translation elongation. This process is crucial for the accurate and efficient synthesis of proteins, involving the coordinated movement of tRNA molecules, mRNA, and conformational changes in the ribosome.
Therapeutic significance:
EF-2's involvement in Spinocerebellar ataxia 26, a disorder characterized by progressive incoordination and cerebellar degeneration, highlights its potential as a therapeutic target. Understanding the role of Elongation factor 2 could open doors to potential therapeutic strategies.